Subcutaneous Xenograft Tumor Articles & Analysis
2 news found
Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. In this preclinical study: continuous delivery of lenalidomide resulted in improvements in the ...
Visit us at our booth #407. We are announcing the launch of our next generation 3D scanner for subcutaneous tumors on mice and rats. We simply named it TumorImager 2TM. We will demonstrate both hands-free and hand-held versions during the convention from June 15th through ...